MD-TELEDYNE-FLIR
8.3.2022 13:03:05 CET | Business Wire | Press release
In a new whitepaper, Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE:TDY), finds that a multi-layered approach, incorporating common architectures and information sharing, among other imperatives, is needed to address the threat to life and property posed by weaponized use of small Unmanned Aerial Systems (sUAS).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220308005265/en/
In January, non-state actors from Yemen utilized small unmanned aerial systems to launch deadly attacks in the United Arab Emirates that destroyed three refueling vehicles and damaged Abu Dhabi’s international airport. Other drone incidents in the Persian Gulf region include a 2019 strike on the world’s largest oil processing facility in Saudi Arabia.
The whitepaper, ‘The Big Problem with Small Drones (and How to Address It) ,’ examines how governments worldwide face a growing need for flexible, tailorable, and affordable Counter-sUAS (C-sUAS) solutions. It looks at current C-sUAS strategy, identifies key challenges, and outlines the critical capabilities governments should consider.
“There’s no ‘silver bullet’ when it comes to countering the huge risks presented by weaponized drones in the hands of bad actors,” said Dr. David Cullin, vice president and general manager of Unmanned and Integrated Solutions at Teledyne FLIR Defense. “What we’ve learned is that governments must address a host of challenges in concert to optimize their defense readiness in the face of UAS attacks.
“Nations around the globe are spending millions of dollars on commercially-built counter-drone solutions to address the immediate risks posed by these threats. But they need to approach the problem smartly, both from a technology and cost perspective. Our new whitepaper offers a number of insights from our team of experts,” Cullin adds.
Key findings include:
- State and non-state actors are increasingly employing military- and consumer-grade drones to attack personnel, facilities and critical infrastructure
- Counter-drone solutions must be cost effective, leveraging existing technologies through common electronic architectures and standard interfaces to ensure rapid integration of hardware and software upgrades
- Solutions must be modular, interoperable and multi-domain; easily transportable; and capable of detecting drone swarms
- Modern C-sUAS must be able to operate in contested environments where the ability to find, track, target, engage and assess threats can be disrupted by peer adversaries’ electronic warfare capabilities
- Current and future C-sUAS systems must be flexible in employing both hard kill (kinetic) and soft kill (non-kinetic) countermeasures, allowing them to operate anywhere in the world in accordance with local restrictions and rules of engagement.
As the paper sums up, ‘The threat of small drones in the wrong hands promises to remain significant for government and military decision-makers as they seek to defend forward-deployed units, airports, power grids, and other critical infrastructure. Only the deployment of mature, flexible, and cost effective C-sUAS solutions will provide the required levels in protection as this threat continues to evolve at pace.”
About Teledyne FLIR
Teledyne FLIR, a Teledyne Technologies company, is a world leader in intelligent sensing, unmanned systems, and integrated solutions for defense and industrial markets, with roughly 4,000 employees worldwide. Founded in 1978, the company develops a wide range of advanced technologies to help professionals make better, faster decisions that save lives and livelihoods. To learn more, visit teledyneflir.com or follow @flir. #AnyThreatAnywhere
About Teledyne Technologies
Teledyne Technologies is a leading provider of sophisticated digital imaging products and software, instrumentation, aerospace and defense electronics, and engineered systems. Teledyne's operations are primarily located in the United States, the United Kingdom, Canada, and Western and Northern Europe. For more information, visit Teledyne's website at www.teledyne.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220308005265/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
